Bladder cancer laboratory findings: Difference between revisions

Jump to navigation Jump to search
 
(12 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Bladder cancer}}
{{Bladder cancer}}
Please help WikiDoc by adding more content here. It's easy!  Click  [[Help:How_to_Edit_a_Page|here]] to learn about editing.
{{CMG}}, {{SCC}} {{AE}} {{F.K}}, {{SC}}
==Overview==
Laboratory findings consistent with the diagnosis of bladder cancer include blood in the urine and abnormal cells in urine cytology. [Tumor marker]] tests include ladder tumour–associated antigen (BTA), uclear matrix proteins (NMP) and mucin and carcinoembryonic antigen (CEA).


{{SCC}}
==Overview==
==Laboratory Findings==
==Laboratory Findings==
===Cystoscopy===
*Laboratory findings consistent with the diagnosis of bladder cancer include:<ref name="pmid18660854">{{cite journal |vauthors=Shariat SF, Karam JA, Lotan Y, Karakiewizc PI |title=Critical evaluation of urinary markers for bladder cancer detection and monitoring |journal=Rev Urol |volume=10 |issue=2 |pages=120–35 |date=2008 |pmid=18660854 |pmc=2483317 |doi= |url=}}</ref><ref name="pmid20161673">{{cite journal |vauthors=Villicana P, Whiting B, Goodison S, Rosser CJ |title=Urine-based assays for the detection of bladder cancer |journal=Biomark Med |volume=3 |issue=3 |pages=265 |date=June 2009 |pmid=20161673 |pmc=2819730 |doi=10.2217/bmm.09.23 |url=}}</ref><ref name="pmid11306356">{{cite journal |vauthors=Grossfeld GD, Litwin MS, Wolf JS, Hricak H, Shuler CL, Agerter DC, Carroll PR |title=Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy--part I: definition, detection, prevalence, and etiology |journal=Urology |volume=57 |issue=4 |pages=599–603 |date=April 2001 |pmid=11306356 |doi= |url=}}</ref>
The gold standard of diagnosing bladder cancer is urine cytology and transurethral (through the urethra) cystoscopy.
* Complete blood count
Urine cytology can be obtained in voided urine or at the time of the cystoscopy ("bladder washing").
:* Low [[red blood cell]] count
Many patients with a history, signs, and symptoms suspicious for bladder cancer are referred to a [[urology|urologist]] or other physician trained in [[cystoscopy]], a procedure in which a flexible tube bearing a camera and various instruments is introduced into the bladder through the [[urethra]]. Suspicious lesions may be biopsied and sent for [[surgical pathology|pathologic analysis]].
:*Elevated [[alkaline phosphatase]]
 
* [[Urinalysis]]
===Urine tests===
:* Hematuria
The laboratory checks the urine for blood, cancer cells, and other signs of disease. Cytology is very specific (a positive result is highly indicative of bladder cancer) but suffers from low sensitivity (a negative result does not exclude the diagnosis of cancer). There are newer urine bound markers for the diagnosis of bladder cancer. These markers are more sensitive but not as specific as urine cytology. They are much more expensive as well.
* Urine cytology
:* Abnormal cells in the urine
* [[Tumor marker]] tests
:* Bladder tumour–associated antigen (BTA)
:* Nuclear matrix proteins (NMP)
:* Mucin and carcinoembryonic antigen (CEA)


==References==
==References==
{{reflist|2}}
{{reflist|2}}
{{Tumors}}


{{WH}}
{{WH}}
{{WS}}
{{WS}}


[[Category:Needs content]]
[[Category:Disease]]
[[Category:Types of cancer]]
[[Category:Urology]]
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Nephrology]]
[[Category:Surgery]]

Latest revision as of 15:12, 25 July 2018

Bladder cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Bladder cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Electrocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Biopsy

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Bladder cancer laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Bladder cancer laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Bladder cancer laboratory findings

CDC on Bladder cancer laboratory findings

Bladder cancer laboratory findings in the news

Blogs on Bladder cancer laboratory findings

Directions to Hospitals Treating Bladder cancer

Risk calculators and risk factors for Bladder cancer laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Steven C. Campbell, M.D., Ph.D. Associate Editor(s)-in-Chief: Farima Kahe M.D. [2], Shanshan Cen, M.D. [3]

Overview

Laboratory findings consistent with the diagnosis of bladder cancer include blood in the urine and abnormal cells in urine cytology. [Tumor marker]] tests include ladder tumour–associated antigen (BTA), uclear matrix proteins (NMP) and mucin and carcinoembryonic antigen (CEA).

Laboratory Findings

  • Laboratory findings consistent with the diagnosis of bladder cancer include:[1][2][3]
  • Complete blood count
  • Hematuria
  • Urine cytology
  • Abnormal cells in the urine
  • Bladder tumour–associated antigen (BTA)
  • Nuclear matrix proteins (NMP)
  • Mucin and carcinoembryonic antigen (CEA)

References

  1. Shariat SF, Karam JA, Lotan Y, Karakiewizc PI (2008). "Critical evaluation of urinary markers for bladder cancer detection and monitoring". Rev Urol. 10 (2): 120–35. PMC 2483317. PMID 18660854.
  2. Villicana P, Whiting B, Goodison S, Rosser CJ (June 2009). "Urine-based assays for the detection of bladder cancer". Biomark Med. 3 (3): 265. doi:10.2217/bmm.09.23. PMC 2819730. PMID 20161673.
  3. Grossfeld GD, Litwin MS, Wolf JS, Hricak H, Shuler CL, Agerter DC, Carroll PR (April 2001). "Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy--part I: definition, detection, prevalence, and etiology". Urology. 57 (4): 599–603. PMID 11306356.

Template:WH Template:WS